Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Recibokibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Recibokibart: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lunbotinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Lunbotinib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vusolimogene oderparepvec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Vusolimogene oderparepvec: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Hydromethylthionine mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Hydromethylthionine mesylate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tinlarebant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tinlarebant: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Glepaglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Glepaglutide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Darleukin/fibromun Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Darleukin/fibromun: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bamlanivimab/Etesevimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Bamlanivimab/Etesevimab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tinengotinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tinengotinib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Olatorepatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Olatorepatide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ribupatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Ribupatide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Levamlodipine/Bisoprolol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Levamlodipine/Bisoprolol: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.